| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Technical Briefs |
1 Biochemistry, 2 Emergency, and3 Cardiology Departments, Hospital de la Santa, Creu i Sant Pau, Barcelona, Spain;4 Biochemistry and Molecular Biology Department, Universitat Autònoma, Barcelona, Spain
aaddress correspondence to this author at: Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Avinguda Sant Antoni Maria Claret 167, 08025 Barcelona, Spain; fax 34-93-2919196, e-mail jordonez@hsp.santpau.es
| The first 300 words of the full text of this article appear below. |
Ischemia-modified albumin (IMA) has been proposed as a biological marker of myocardial ischemia (1)(2). Exposure to ischemic myocardium modifies circulating albumin at its NH2 terminus by different mechanisms, and this modification is the basis of IMA measurement by the albumin cobalt binding (ACB) test (3). The tissue-specific nature of the mechanism by which ischemia modifies albumin remains undetermined. Together with a nondiagnostic electrocardiogram and negative troponin values, IMA concentrations within the reference interval have high negative predictive value of myocardial ischemia in patients with suspected acute coronary syndromes (1)(2). However, IMA cardiospecificity has not been validated and needs an evidence base before routine clinical use. A recent report showed significant IMA increases 24–48 h after a marathon race, with exercise-promoted gastrointestinal and/or delayed skeletal muscle ischemia being evoked as possible causes of such increases (4). However, because IMA has shown rapid kinetics of increase (in minutes) and return to baseline no longer than 12 h after angioplastic procedures (5), long-duration skeletal muscle ischemia (i.e., occurring during marathons) does not appear to be the most appropriate model to investigate the effect of such ischemia on IMA values or the kinetics of IMA occurring during acute coronary syndromes. The aim of this work was to analyze the possible contribution of skeletal muscle ischemia to IMA by investigating its short-term kinetics in an isolated skeletal-muscle ischemia model. Because lactate and ammonia concentrations increase sharply after a forearm ischemia test, their possible influence in the ACB assay was studied.
Ten healthy volunteers (4 men and 6 women) from our laboratory staff (age range, 48–61 years; median, 53 years) with no personal or family history of cardiovascular disease and no known cardiovascular risk factors after a medical examination underwent a forearm
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  P O Collinson and D C Gaze Ischaemia-modified albumin: clinical utility and pitfalls in measurement J. Clin. Pathol., September 1, 2008; 61(9): 1025 - 1028. [Full Text] [PDF]
|
|
|
|
 |
|
 A Gunduz, A Mentese, S Turedi, S C Karahan, U Mentese, O Eroglu, S Turkmen, I Turan, U Ucar, R Russell, et al. Serum ischaemia-modified albumin increases in critical lower limb ischaemia Emerg. Med. J., June 1, 2008; 25(6): 351 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Talwalkar, M. Bon-Homme, J. J. Miller, and R. J. Elin Ischemia Modified Albumin, a Marker of Acute Ischemic Events: A Pilot Study Ann. Clin. Lab. Sci., January 1, 2008; 38(2): 132 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Roy and J. C. Kaski IMA the role of oxidative stress Europace, September 1, 2007; 9(9): 854 - 854. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kalay, Y. Cetinkaya, and I. Ozdogru Ischemia-Modified Albumin and Myocardial Ischemia J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2375 - 2375. [Full Text] [PDF]
|
|
|
|
|
|
D. Roy and J. C. Kaski Ischemia-Modified Albumin: The Importance of Oxidative Stress J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2375 - 2376. [Full Text] [PDF]
|
|
|
|
|
|
E. Sbarouni, P. Georgiadou, G. N. Theodorakis, and D. Th. Kremastinos Ischemia-Modified Albumin in Relation to Exercise Stress Testing J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2482 - 2484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Middleton, R. Shave, K. George, G. Whyte, J. Forster, D. Oxborough, D. Gaze, and P. Collinson Novel application of flow propagation velocity and ischaemia-modified albumin in analysis of postexercise cardiac function in man Exp Physiol, May 1, 2006; 91(3): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. van der Zee, H. J. Verberne, J. P. van Straalen, G. T.B. Sanders, B. L.F. Van Eck-Smit, R. J. de Winter, and J. C. Fischer Ischemia-Modified Albumin Measurements in Symptom-Limited Exercise Myocardial Perfusion Scintigraphy Reflect Serum Albumin Concentrations but Not Myocardial Ischemia Clin. Chem., September 1, 2005; 51(9): 1744 - 1746. [Full Text] [PDF]
|
|
|
|
|
|
F. S. Apple, A. H.B. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R. H. Christenson, M. Mockel, O. Danne, et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome Clin. Chem., May 1, 2005; 51(5): 810 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Roy, J. Quiles, R. Sharma, M. Sinha, P. Avanzas, D. Gaze, and J. C. Kaski Ischemia-Modified Albumin Concentrations in Patients with Peripheral Vascular Disease and Exercise-Induced Skeletal Muscle Ischemia Clin. Chem., September 1, 2004; 50(9): 1656 - 1660. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
